TRENDING KEYWORDS
Biogen (BIIB, $239.92) shares fall, after Samsung BioLogics denies takeover report
Biogen shares took a hit, after Samsung BioLogics denied a report that claimed that it's discussing takeover plans that at a value of around $42 billon.
Korea Economic Daily report mentioned ties between the two groups including FDA approval of key treatments, as well as Biogen's 50% stake minus one share in biosimilars unit Samsung Bioepis Co. The report also stated plans from the Samsung Group to invest more than $200 billion over the next three years in order to expand its semiconductor, display and biopharmaceuticals business.
But Samsung BioLogics called the report "untrue".
BIIB in downward trend: price dove below 50-day moving average on May 05, 2022
BIIB moved below its 50-day Moving Average on May 05, 2022 date and that indicates a change from an upward trend to a downward trend. In 34 of 49 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 69%.
Current price $198.38 crossed the support line at $263.14 and is trading between $263.14 support and $-148.54 support lines. Throughout the month of 04/13/22 - 05/16/22, the price experienced a -7% Downtrend, while the week of 05/09/22 - 05/16/22 shows a +6% Uptrend.
The Momentum Indicator moved below the 0 level on April 22, 2022. You may want to consider selling the stock, shorting the stock, or exploring put options on BIIB as a result. In 56 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 62%.
The Moving Average Convergence Divergence Histogram (MACD) for BIIB turned negative on April 26, 2022. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 32 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 65%.
The 10-day Moving Average for BIIB crossed bearishly below the 50-day moving average on May 05, 2022. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIIB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 57%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BIIB's RSI Oscillator exited the oversold zone, 16 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 57%.
The Stochastic Indicator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 39 of 59 cases where BIIB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 66%.
Following a +4.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIIB advanced for three days, in 187 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
BIIB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 79 of 139 cases where BIIB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 57%.
Tickeron has a negative outlook on this ticker and predicts a further decline by more than 4.00% within the next month with a likelihood of 78%. During the last month, the daily ratio of advancing to declining volumes was 1 to 2.05.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIIB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock worse than average.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.594) is normal, around the industry mean (6.843). P/E Ratio (20.367) is within average values for comparable stocks, (85.171). BIIB's Projected Growth (PEG Ratio) (8.460) is slightly higher than the industry average of (3.164). BIIB's Dividend Yield (0.000) is considerably lower than the industry average of (0.026). P/S Ratio (2.731) is also within normal values, averaging (3.807).
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. BIIB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 48 (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
The average market capitalization across the Pharmaceuticals: Major Industry is 77.7B. The market cap for tickers in the group ranges from 226K to 465.4B. JNJ holds the highest valuation in this group at 465.4B. The lowest valued company is NEWG at 226K.
The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was 1.03%. For the same Industry, the average monthly price growth was -4.83%, and the average quarterly price growth was -7.85%. GIFOF experienced the highest price growth at 17.34%, while DCHPF experienced the biggest fall at -28.83%.
- 5/7/22 5:28 AM: Biogen (BIIB, $193.61) was a top loser this week, declining -6.67%
- 4/20/22 8:58 AM: Biogen (BIIB, $223.02) was a top weekly gainer, with a +7.19% jump
- 3/22/22 5:13 AM: Biogen (BIIB, $206.81) was a top weekly gainer, with a +6.73% jump
The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -5.23%. For the same stocks of the Industry, the average monthly volume growth was 12.33% and the average quarterly volume growth was -2.15%
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Stocks in the group have a Negative Outlook today, backed by the MA200MA50 Indicator. Tickeron has a negative outlook on this group and predicts a further decline by more than 4.00% within the next month with a likelihood of 48%. During the last month, the daily ratio of advancing to declining volumes was 1 to 1.13.
27 stocks in the group of tickers confirmed the negative outlook based on the Declines indicator with average odds of 54%.
The most notable companies in this group are Johnson & Johnson (NYSE:JNJ), Pfizer (NYSE:PFE), Eli Lilly & Co (NYSE:LLY), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NASDAQ:AZN), Bristol-Myers Squibb Co (NYSE:BMY), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Biogen (NASDAQ:BIIB).
The average market capitalization across the group is 97.5B. The market cap for tickers in the group ranges from 23.6M to 465.4B. JNJ holds the highest valuation in this group at 465.4B. The lowest valued company is CRXT at 23.6M.
- 2/26/22 6:56 AM: Johnson & Johnson (JNJ, $166), market cap jumped by $20.7B
The average weekly price growth across all stocks in the group was 2.28%. For the same group, the average monthly price growth was -5.06%, and the average quarterly price growth was -4.92%. GRFS experienced the highest price growth at 11.07%, while RHHBY experienced the biggest fall at -8.83%.
- 5/12/22 5:38 AM: GlaxoSmithKline (GSK, $42.53) was a top loser this week, declining -5.82%
- 5/10/22 5:36 AM: Mayne Pharma Group (MAYNF, $0.19) was a top loser this week, declining -9.52%. Expect a Downtrend reversal
- 5/7/22 5:28 AM: Biogen (BIIB, $193.61) was a top loser this week, declining -6.67%
The average weekly volume growth across all stocks in the group was -29.89%. For the same stocks of the group, the average monthly volume growth was 59.4% and the average quarterly volume growth was 92.07%
- 5/5/22 4:51 AM: The volume for Clarus Therapeutics Holdings stock increased for two consecutive days, resulting in a record-breaking daily growth of 192% of the 65-Day Volume Moving Average
- 5/5/22 4:51 AM: The volume for Horizon Therapeutics Public stock increased for one day, resulting in a record-breaking daily growth of 246% of the 65-Day Volume Moving Average
- 4/22/22 6:34 AM: The volume for Clarus Therapeutics Holdings stock increased for one day, resulting in a record-breaking daily growth of 1,022% of the 65-Day Volume Moving Average
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Latest blogs by Abhoy Sarkar
Top Blogs
